SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001493152-23-009563
Filing Date
2023-03-30
Accepted
2023-03-29 19:07:47
Documents
78
Period of Report
2022-12-31

Document Format Files

Seq Description Document Type Size
1 form10-k.htm   iXBRL 10-K 1640080
2 ex4-5.htm EX-4.5 36083
3 ex31-1.htm EX-31.1 16326
4 ex31-2.htm EX-31.2 16351
5 ex32.htm EX-32 6794
  Complete submission text file 0001493152-23-009563.txt   6990259

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE pvct-20221231.xsd EX-101.SCH 56207
7 XBRL CALCULATION FILE pvct-20221231_cal.xml EX-101.CAL 62285
8 XBRL DEFINITION FILE pvct-20221231_def.xml EX-101.DEF 224583
9 XBRL LABEL FILE pvct-20221231_lab.xml EX-101.LAB 429834
10 XBRL PRESENTATION FILE pvct-20221231_pre.xml EX-101.PRE 343083
72 EXTRACTED XBRL INSTANCE DOCUMENT form10-k_htm.xml XML 1010972
Mailing Address 10025 INVESTMENT DRIVE SUITE 250 KNOXVILLE TN 37932
Business Address 10025 INVESTMENT DRIVE SUITE 250 KNOXVILLE TN 37932 865-769-4011
PROVECTUS BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000315545 (see all company filings)

IRS No.: 900031917 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-36457 | Film No.: 23776722
SIC: 2834 Pharmaceutical Preparations